VP
LYEL icon

venBio Partners’s Lyell Immunopharma LYEL Stock Holding History

venBio Partners’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.74M Hold
337,697
– – 0.91% 7
2026
Q1 		$6.77M Hold
337,697
– – 2.41% 5
2025
Q4 		$10.4M Sell
337,697
-135,782
-29% -$3.04M 4.81% 5
2025
Q3 		$7.69M Hold
473,479
– – 4.36% 5
2025
Q2 		$4.19M Buy
473,479
+118,369
+33% +$1.08M 3.65% 4
2025
Q1 		$3.82M Hold
355,110
– – 3.09% 6
2024
Q4 		$4.55M Buy
+355,110
New +$7.04M 2.66% 7

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

venBio Partners's LYEL Position: Q2 2026 in Review

venBio Partners held its Lyell Immunopharma (LYEL) position steady in Q2 2026 at 337,697 shares worth $4.74M. The position accounts for 0.91% of the portfolio, ranked #7.

venBio Partners first reported a position in LYEL in Q4 2024 and has held it in 7 quarters since. The position peaked at $10.4M in Q4 2025. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • venBio Partners held 337,697 shares of Lyell Immunopharma worth $4.74M as of Q2 2026.
  • venBio Partners left its Lyell Immunopharma share count unchanged in Q2 2026.
  • Lyell Immunopharma made up 0.91% of venBio Partners's portfolio in Q2 2026, its #7 holding.
  • venBio Partners first reported a position in Lyell Immunopharma in Q4 2024 and has held it in 7 quarters since.
  • venBio Partners's Lyell Immunopharma position peaked at $10.4M in Q4 2025.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on venBio Partners's 13F filing for Q2 2026, filed 14 Aug 2026.